Safe Antibiotic Options for UTI Treatment in CKD Stage 4

First-Line Options for Lower UTIs (Cystitis)

Fosfomycin 3g as a single oral dose is recommended for uncomplicated urinary tract infections with minimal renal adjustment needed, according to the Praxis Medical Insights and Journal of Microbiology, Immunology and Infection 1, 2
Trimethoprim-sulfamethoxazole can be used with appropriate dose reduction (half dose for creatinine clearance 15-30 mL/min) as recommended by Clinical Infectious Diseases and Praxis Medical Insights 3, 1
Single-dose aminoglycoside therapy may be effective for simple cystitis, especially when dealing with resistant organisms, as suggested by Journal of Microbiology, Immunology and Infection and Praxis Medical Insights 2, 1
Nitrofurantoin should be avoided in CKD stage 4 (GFR <30 mL/min) due to reduced efficacy and increased risk of peripheral neuropathy, according to Praxis Medical Insights 1

For hospitalized patients requiring IV therapy, consider ceftazidime-avibactam with appropriate renal dose adjustment, as recommended by Praxis Medical Insights and Journal of Microbiology, Immunology and Infection 1, 2
Meropenem-based combinations can be used with appropriate renal dosing for more severe infections, according to Praxis Medical Insights 1

Use the shortest effective duration of antibiotics, generally no longer than 7 days for uncomplicated cases, as recommended by Praxis Medical Insights 1

Trimethoprim-sulfamethoxazole: For creatinine clearance 15-30 mL/min, use half the standard dose; for <15 mL/min, use half dose or consider alternative agent, as recommended by Clinical Infectious Diseases 3

Failing to obtain cultures before starting antibiotics, which is crucial for targeted therapy, as recommended by Praxis Medical Insights 1
Using nitrofurantoin in advanced CKD (GFR <30 mL/min) as it can produce toxic metabolites, according to Praxis Medical Insights 1
Using aminoglycosides for prolonged therapy, as retrospective studies have associated them with faster kidney function decline, as reported by American Journal of Kidney Diseases 4
Unnecessary treatment of asymptomatic bacteriuria, which is not recommended, according to Praxis Medical Insights 1

For patients receiving potentially nephrotoxic antibiotics, more frequent monitoring of renal function may be necessary, as recommended by American Journal of Kidney Diseases 4

For patients on hemodialysis, consider administering antibiotics after dialysis sessions to prevent drug removal, as recommended by Praxis Medical Insights 1
Avoid NSAIDs and COX-2 inhibitors during antibiotic treatment as they may further impair residual kidney function, according to American Journal of Kidney Diseases 4

The Infectious Diseases Society of America recommends ceftazidime-avibactam 2.5g IV every 8 hours with renal dose adjustment as the preferred treatment for ESBL-producing organisms in CKD patients 5
For carbapenem-resistant Enterobacterales (CRE), the European Society of Clinical Microbiology and Infectious Diseases suggests using meropenem-vaborbactam or ceftazidime-avibactam if active in vitro for severe infections 5
Cefiderocol is recommended for CRE carrying metallo-β-lactamases resistant to other agents, according to the Clinical Microbiology and Infection guidelines 5
For non-severe infections, the guidelines recommend using old antibiotics active in vitro, such as aminoglycosides including plazomicin, preferred over tigecycline for cUTI 5
Combination therapy is not recommended for CRE infections susceptible to new β-lactam/β-lactamase inhibitor combinations, as stated by the Clinical Microbiology and Infection guidelines 5